Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Urogenital Cancer Genitourinary Cancer—Kidney and Bladder

Genitourinary Cancer—Kidney and Bladder

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426
 
Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, et al.
Clinical trial information: NCT02853331
 
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
 
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, et al.
 Clinical trial information: NCT03428217
 
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
 
Robert J. Motzer, Camillo Porta, Boris Alekseev,  et al.
 Clinical trial information: NCT02811861
 
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
 
Matt D. Galsky, Siamak Daneshmand, Kevin G. Chan, et al.
Clinical trial information: NCT03558087
 
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
 
Arjun Vasant Balar, Matthew I. Milowsky, Peter H. O'Donnell, et al.
Clinical trial information: NCT02621151
 
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
 
Xavier Garcia del Muro, Begoña P. Valderrama, Ana Medina, et al.
 Clinical trial information: NCT03702179
 
A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
 
Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, et al.
 Clinical trial information: NCT02567409
 
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
 
Peter H. O'Donnell, Arjun Vasant Balar, Jacqueline Vuky, et al.
 Clinical trial information: NCT02335424
 
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
 
Arjun Vasant Balar, Victor Moreno, Eric Angevin, et al.
Clinical trial information: NCT02723955